Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.67 |
| ▸ | FYN | P06241 | 7/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.62 |
| ▸ | IKBKB | O14920 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037594 | 1.00 | PIM1 (0.67) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3033716 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3036703 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3043588 | 0.89 | PIM1 (0.72) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3043586 | 0.89 | PIM1 (0.72) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3036678 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL2945956 | 0.89 | PIM1 (0.76) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3036675 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3036707 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB | |
| SCHEMBL3033719 | 0.89 | PIM1 (0.66) | PIM1KCNH2FYNMKNK1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-2063962-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | Biogen Idec MA Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008030579-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIM1 363/4885KCNH2 2562/4885FYN 521/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | PIM1 147/4885KCNH2 4576/4885FYN 666/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIM1 363/4885KCNH2 2562/4885FYN 521/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | PIM1 365/4885KCNH2 1604/4885FYN 421/4885 |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | PIM1 138/4885KCNH2 235/4885FYN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.